AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01141972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
Study NCT03597087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia before transurethral resection of the bladder tumor
Description: General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle
Study NCT03597087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: General anaesthesia : propopol~Spinal anaesthesia : bupibacaine
Study NCT02220959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk test
Description: patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
Study NCT01193205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training
Description: 20 weeks of Dialectical Behaviour Therapy Skills Training
Study NCT02282254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overnight intervention
Description: Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
Study NCT02374736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Privigen (Human normal immunoglobulin G (IgG > 98 % purity))
Description: Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL.
Study NCT01072045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Study NCT01072045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Study NCT04288648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound examination
Description: ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
Study NCT03372694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training
Description: Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
Study NCT03372694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
Study NCT00975481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Oral tablet; 20 mg dimebon, single dose
Study NCT00975481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Oral tablet; 40 mg dimebon, single dose
Study NCT00975481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Oral tablet; 60 mg dimebon, single dose
Study NCT02098733 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone/glimepiride
Description: Pioglitazone/glimepiride combination tablets
Study NCT02240849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional pillow
Description: streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
Study NCT02240849 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo general pillow
Study NCT00589056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00589056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00589056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Study NCT00589056 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00589056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00589056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00589056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study NCT00589056 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT06363318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Description: In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
Study NCT06363318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendicectomy
Description: In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
Study NCT00975481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral tablet or capsule; placebo, single dose
Study NCT00975481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: Oral capsule; 1 mg alprazolam, single dose
Study NCT00975481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: Oral capsule; 3 mg alprazolam, single dose
Study NCT00112593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00112593 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT03372694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation Education
Description: General health education
Study NCT03372694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Education
Description: General health education
Study NCT03372694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
Study NCT00579241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound on Temporal Bone
Description: All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
Study NCT02118766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2%
Study NCT02118766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching vehicle control
Study NCT04744389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic Machine Perfusion
Description: The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
Study NCT04744389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Machine Perfusion
Description: Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
Study NCT03872427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03872427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT03872427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03872427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study NCT03872427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03872427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO
Study NCT00112593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
Study NCT00112593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT00112593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO
Study NCT00783263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
Study NCT00783263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin 10 mg
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
Study NCT00783263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
Study NCT02680262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit mailed directly
Description: Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
Study NCT02680262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit on demand
Description: Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure).
Study NCT02680262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second reminder
Description: The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
Study NCT02108171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Study NCT00783263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin 20 mg
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Study NCT02117492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cuff Closure
Description: Closure of the vaginal cuff following hysterectomy.
Study NCT01742663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel 3%
Description: Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
Study NCT01742663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solaraze® (diclofenac sodium) Gel 3%
Description: Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
Study NCT01742663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
Study NCT02313506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education session, Fitbit Flex, and remote coaching by a PT
Description: Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
Study NCT02313506 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 1 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
Study NCT02258191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: telemonitoring
Study NCT02258191 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham telemonitoring
Study NCT04061304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.
Study NCT04061304 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
Study NCT02108171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Study NCT02909205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sensitization / educational program
Description: the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
Study NCT02909205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training / sensitization program
Description: diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
Study NCT02537275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea
Description: tinted contact lens, daily-wear tinted lens
Study NCT02537275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLIKe Shine, Koryo Eyetech Co
Description: clear lens
Study NCT01295632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
Study NCT01295632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: 300 mg capsule, orally, 6 capsules per dose, once each week.
Study NCT01295632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
Study NCT00112593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02144389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel (PZQ)
Description: 40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally
Study NCT02144389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA)
Description: ARA (40% of total fatty acid)
Study NCT02144389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PZQ+ARA
Description: A single dose of PZQ administered seven days in advance of initial treatment with ARA.
Study NCT00643682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational card
Description: A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy.
Study NCT02125812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scaling and systemic moxifloxacin
Description: scaling and root planing (SRP) combined with systemic moxifloxacin
Study NCT02125812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing
Description: scaling and root planing
Study NCT01279954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years.
Study NCT04387591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling(FSN)
Description: In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.